Herantis Pharma Oyj

HRTIS · Nasdaq Helsinki · Healthcare

1.42EUR +1.9%last day

Price as of 2 October 2026

The price over the past year, with dividends: −22.5%

Performance

1 month

−9.1%

1 year

−22.5%

3 years, per year

−0.7%

5 years, per year

−12.0%

Largest fall, 3 years

−79.7%

Below the peak now

−85.9%

Volatility, 1 year

60.4%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

−59.8

Dividend yield

0.0%

Return on equity

−392.4%

Net margin

–

Market value

41 m USD

Quality, value and trend

Where Herantis Pharma stands against every Nordic stock today. 100 is best.

Quality1

Profitability and a sound balance sheet over time. Better than 1% of Nordic stocks.

Value1

The price measured against earnings, assets and cash flow. Better than 1% of Nordic stocks.

Trend18

The price development over the past year. Better than 18% of Nordic stocks.

Combined0

Quality, value and trend together. Better than 0% of Nordic stocks.

About Herantis Pharma

Herantis Pharma Oyj is a company in healthcare, listed on Nasdaq Helsinki. The share trades in EUR. It has around 14 employees.

Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. Herantis Pharma Oyj was incorporated in 2008 and is based in Espoo, Finland.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis